達志科技(300530.SZ):子公司擬與衡陽路橋簽訂電池研究院及中試線建設項目投資人投資建設和運營管理協議
格隆匯9月23日丨達志科技(300530.SZ)公佈,公司全資子公司湖南領湃鼎芯電池研究院有限公司(“鼎芯研究院”)對“電池研究院及中試線建設項目”進行公開招標,由招標代理機構湖南智曜項目管理有限公司於2022年8月18日在湖南省招標投標監管網上公開發布了招標公吿。在履行相應開標、評審、公示等程序後,最終於2022年9月20日確定中標單位為衡陽公路橋樑建設有限公司(“衡陽路橋”),中標暫定總價金額18500.65萬元。鼎芯研究院擬與衡陽路橋簽訂《電池研究院及中試線建設項目投資人投資建設和運營管理協議》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.